Holocene Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Holocene Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.65M	Sell	166,867 -13,982	-8%	-$466K	0.01%	395
2026 Q1	$5.45M	Buy	+180,849	New	+$5.82M	0.01%	388
2025 Q3	–	Sell	-3,053,340	Closed	-$51.2M	–	911
2025 Q2	$51.2M	Sell	3,053,340 -967,288	-24%	-$15.6M	0.12%	168
2025 Q1	$61.8M	Buy	4,020,628 +851,215	+27%	+$15.2M	0.18%	151
2024 Q4	$69.9M	Buy	3,169,413 +957,330	+43%	+$17.4M	0.22%	133
2024 Q3	$39.9M	Sell	2,212,083 -2,374,189	-52%	-$41.6M	0.16%	170
2024 Q2	$74.5M	Sell	4,586,272 -376,184	-8%	-$5.79M	0.31%	97
2024 Q1	$70M	Sell	4,962,456 -295,739	-6%	-$3.73M	0.26%	126
2023 Q4	$54.9M	Buy	5,258,195 +135,422	+3%	+$1.26M	0.21%	142
2023 Q3	$52.3M	Buy	+5,122,773	New	+$47.7M	0.23%	136

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Holocene Advisors's TEVA Position: Q2 2026 in Review

Holocene Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 7.7% in Q2 2026, selling an estimated $466K and leaving 166,867 shares worth $5.65M. The position accounts for 0.01% of the portfolio, ranked #395.

Holocene Advisors first reported a position in TEVA in Q3 2023 and has held it in 10 quarters since. The position peaked at $74.5M in Q2 2024. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Holocene Advisors held 166,867 shares of Teva Pharmaceuticals worth $5.65M as of Q2 2026.
Holocene Advisors sold 13,982 Teva Pharmaceuticals shares in Q2 2026, an estimated $466K.
Teva Pharmaceuticals made up 0.01% of Holocene Advisors's portfolio in Q2 2026, its #395 holding.
Holocene Advisors first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
Holocene Advisors's Teva Pharmaceuticals position peaked at $74.5M in Q2 2024.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.